Seroprevalence and risk factors of HBV, HCV and HIV among hemodialysis patients: a multicenter cross-sectional study from Damascus Syria

被引:5
作者
Altinawe, Jehan [1 ]
Akkawi, Muhammad Eid [2 ]
Helu, Nihad Kharrat [1 ]
Hassan, Qusai [3 ]
Nattouf, Abdul-Hakim [1 ]
机构
[1] Damascus Univ, Fac Pharm, Dept Pharmaceut & Pharmaceut Technol, Damascus, Syria
[2] Int Islamic Univ Malaysiam, Fac Pharm, Dept Pharm Practice, Jalan Sultan Ahmad Shah, Kuantan 25200, Pahang, Malaysia
[3] Damascus Univ, Fac Med, Dept Internal Med, Damascus, Syria
关键词
Hemodialysis; Infection; Hepatitis; HBV; HCV; HIV; Chronic kidney disease; Damascus; Syria; HEPATITIS-C VIRUS; DIALYSIS PATIENTS; PREVALENCE; INFECTIONS; EPIDEMIOLOGY;
D O I
10.1186/s12879-024-09177-4
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective The aim of this study is to determine the prevalence rates of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) infections among hemodialysis (HD) patients as well as to identify associated risk factors. Methodology A multicenter cross-sectional study involved patients who had been on HD for at least three months. The study was conducted at five HD centers in Damascus, Syria from August 2019 to September 2021. HBsAg, HCV-Ab and HIV (antibody/antigen) seropositivity were identified using the third generation ELISA technique. Patients' information was extracted from their records and by face-to-face interview. Multiple logistic regression models were applied to identify risk factors associated with HBV or HCV seropositivity. The significance level was set at 5%. Results A total of 637 patients were included in the study with a mean age (SD) of 50.5 (15.6) years and 56.7% of them were men. The dialytic age ranged from one to thirty years with a mean (SD) of 6.10 (5.6) years. The prevalence of positive hepatitis B surface antigen, anti-HCV, co-infection of HBV and HCV, and anti-HIV (antibody/antigen) were 3.2%, 22.1%, 0.7%, and 0%, respectively. After controlling for co-variables, hepatitis B vaccine was the only predictor of seropositivity of HBV (OR: 0.15, 95% CI: 0.057-0.393, P < 0.001), as it significantly protected against contracting HBV. On the other hand, the dialytic age (OR: 1.42, 95% CI: 1.12-1.94, P = 0.032) and the dialysis center were significant factors affecting the prevalence of HCV. Conclusions The prevalence of HCV and HBV infections among HD patients in Damascus, Syria has decreased remarkably compared with the results from 2001. Nevertheless, it is still considered relatively high. Thus, there is an urgent need to strengthen the prevention and control measures for viral infection transmission in HD centers in Damascus.
引用
收藏
页数:8
相关论文
共 44 条
[1]  
Abdalla EAM., 2017, IOSR J Dent Med Sci, V16, P83, DOI [10.9790/0853-1603088388, DOI 10.9790/0853-1603088388]
[2]  
Abou Rached Antoine, 2016, World J Nephrol, V5, P101, DOI 10.5527/wjn.v5.i1.101
[3]  
Abumwais J, 2010, Iran J Virol, V4, P38
[4]   The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis [J].
Adane, Tiruneh ;
Getawa, Solomon .
PLOS ONE, 2021, 16 (06)
[5]   Hepatitis B and C prevalence among hemodialysis patients in the West Bank hospitals, Palestine [J].
Al Zabadi, Hamzeh ;
Rahal, Hani ;
Fuqaha, Rasha .
BMC INFECTIOUS DISEASES, 2016, 16
[6]  
Al-Jamal M, 2009, SAUDI J KIDNEY DIS T, V20, P488
[7]   Hand contamination with hepatitis C virus in staff looking after hepatitis C-positive hemodialysis patients [J].
Alfurayh, O ;
Sabeel, A ;
Al Ahdal, MN ;
Almeshari, K ;
Kessie, G ;
Hamid, M ;
Dela Cruz, DM .
AMERICAN JOURNAL OF NEPHROLOGY, 2000, 20 (02) :103-106
[8]  
Almezgagi MM., 2020, PSM Microbiol, V5, P32
[9]   Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis [J].
Ashkani-Esfahani, Soheil ;
Alavian, Seyed Moayed ;
Salehi-Marzijarani, Mohammad .
WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (01) :151-166
[10]  
Assi WT., 2017, Res J Pharm Technol, V10, P1301, DOI [10.5958/0974-360X.2017.00230.X, DOI 10.5958/0974-360X.2017.00230.X]